Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
October 20, 2017 08:00 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of a poster addressing results with the company’s pan-caspase inhibitor...
EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
October 18, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the European Medicines Agency (EMA) has granted orphan designation to Conatus’ drug...
Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer
August 31, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus to Present at Rodman & Renshaw Global Investment Conference
August 29, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the...
Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
August 14, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-NF, a randomized, double-blind, placebo-controlled,...
Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates
August 02, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results
July 26, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2017, after the...
Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment
July 06, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that its exclusive license with Novartis for the global development and commercialization of...
FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
June 26, 2017 07:00 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
June 16, 2017 07:00 ET
|
Conatus Pharmaceuticals Inc.
GALWAY, Ireland, June 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that a poster addressing preclinical results with the company’s lead pancaspase...